

14th Congress of the International Ocular Inflammation Society (IOIS)

sioje

& The 4th International Assembly of Ocular Inflammation Societies

Fluocinolone acetonide implant (lluvien[®]) in Birdshot cystoid macular edema



Pedro Silva¹, Pedro Simões¹, Miguel Cordeiro¹, Carolina Bruxelas¹, Marta Guedes¹ 1 - Hospital Egas Moniz – CHLO Financial interests: none

Background: The development of cystoid macular edema (CME) in Birdshot chorioretinopathy (BSCR) occurs in up to 50% of patients and the mainstay of therapy are corticosteroids administered orally, by intravitreal injection or intravitreal implant.


Patients & Methods: The authors present 2 cases of BSCR with chronic CME treated with fluocionolone acetonide

implant (Iluvien®). Both cases were also under treatment with corticoid-sparing drugs.


Results: Both cases of BSCR presented with a chronic CME refractory to oral immunossupression.

<u>Case1</u>: After 6 dexamethasone implants (Ozurdex[®]), 3 in each eye, with a 6 month interval between each implant, the patient was treated with the fluocionolone acetonide implant (lluvien[®]) and catatact surgery in both eyes. The cataract development seemed to be secondary to previous treatment with intravitreal steroids.

<u>**Case2:</u>** The second patient was treated initially with 2 dexamethasone implants (Ozurdex[®]), also with a 6 month gap, in the left eye, and then with a fluocionolone acetonide implant (Iluvien[®]).</u>




<u>Therapy and Outcome:</u> In both cases, there was no recurrence of CME after 6 months of fluocionolone acetonide implant (Iluvien[®]).




200 µm

Figures case 1: OCT-SD one month after the fluocionolone acetonide implant (Iluvien®)



Figures case 2: OCT-SD one month after the fluocionolone acetonide implant (lluvien[®]).



Figures case 2: OCT-SD six months after the fluocionolone acetonide implant (lluvien®)

Figures case 1: OCT-SD six months after the fluocionolone acetonide implant (lluvien®)

Conclusions: Treatment with intravitreal corticosteroid implants is effective in refractory CME associated to BSCR. The

fluocinolone acetonide implant may be as effective as the dexamethasone implant with less frequent injections